Prognostic factors in adult acute lymphoblastic leukaemia
- 2 August 2010
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 150 (4), 389-405
- https://doi.org/10.1111/j.1365-2141.2010.08246.x
Abstract
Treatment of acute lymphoblastic leukaemia (ALL) in adults presents a formidable challenge. While overall results have improved over the past 3 decades, the long-term survival for patients aged less than 60 years is only in the range of 30-40% and is 10-15% if between 60 and 70 years and <5% for those over 70 years. The historic lack of clear-cut biological prognostic factors has led to over- or under-treatment of some patients. Response to initial therapy is an important prognosticator of outcome based on disease biology, as well as pharmacogenetics, which include the patient's response to drugs given. The more widespread availability of allogeneic transplantation and reduced-intensity regimens for older patients have opened up this curative modality to a greater number of patients. Hopefully, those options, as well as novel cytogenetic and molecular markers, will enable a better selection of patients who undergo intensive therapies and finally break the 30-40% cure barrier for adults with ALL.Keywords
This publication has 103 references indexed in Scilit:
- Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemiaBritish Journal of Pharmacology, 2009
- NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemiaLeukemia, 2009
- Minimal Residual Disease in Acute Lymphoblastic LeukemiaSeminars in Hematology, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2009
- The role of NOTCH1 signaling in T-ALLHematology, 2009
- A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B‐cell (CD20+) non‐Hodgkin lymphoma and mature B‐cell acute lymphoblastic leukemia: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2008
- Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remissionBlood, 2008
- Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell linesLeukemia Research, 2008
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Blood, 2006
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004